Tango Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: TNGX · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1819133
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Tango Therapeutics inked a big deal and sold some stock, filing an 8-K on Oct 23rd.
AI Summary
On October 23, 2025, Tango Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Tango Therapeutics, Inc. is incorporated in Delaware and its principal executive offices are located in Boston, MA.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 001-39485 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1195036 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Registrant
- October 23, 2025 (date) — Date of earliest event reported
- BCTG Acquisition Corp. (company) — Former company name
- 201 Brookline Avenue Suite 901, Boston, MA 02215 (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Tango Therapeutics, Inc. on October 23, 2025?
The filing states that an "Entry into a Material Definitive Agreement" is an item of disclosure, but the specific details of the agreement are not provided in this excerpt.
What were the details of the unregistered sales of equity securities reported by Tango Therapeutics, Inc.?
The filing lists "Unregistered Sales of Equity Securities" as an item of disclosure, but the specifics of these sales are not detailed in the provided text.
What financial statements and exhibits were filed by Tango Therapeutics, Inc.?
The filing indicates that "Financial Statements and Exhibits" were filed, but the content of these documents is not specified in this excerpt.
When did Tango Therapeutics, Inc. change its name from BCTG Acquisition Corp.?
The filing states the Date of Name Change was July 23, 2020.
What is Tango Therapeutics, Inc.'s fiscal year end?
Tango Therapeutics, Inc.'s fiscal year end is December 31.
Filing Stats: 1,950 words · 8 min read · ~7 pages · Grade level 14.3 · Accepted 2025-10-24 06:17:49
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TNGX The Nasdaq Global Ma
- $8.66 b — ffered and sold at an offering price of $8.66 before deducting underwriting discounts a
- $8.659 — ffered and sold at an offering price of $8.659 which is equal to the offering price pe
- $0 — an initial exercise price per share of $0.001, subject to certain adjustments. Th
- $197 million — ayable by the Company are approximately $197 million. The Company intends to use the net pro
- $8.66 — 's Common Stock, at a purchase price of $8.66 per share. The aggregate gross proceeds
- $15 m — Private Placement will be approximately $15 million, before deducting offering commis
Filing Documents
- d80580d8k.htm (8-K) — 38KB
- d80580dex11.htm (EX-1.1) — 206KB
- d80580dex41.htm (EX-4.1) — 65KB
- d80580dex51.htm (EX-5.1) — 9KB
- d80580dex101.htm (EX-10.1) — 147KB
- 0001193125-25-249302.txt ( ) — 706KB
- tngx-20251023.xsd (EX-101.SCH) — 3KB
- tngx-20251023_lab.xml (EX-101.LAB) — 18KB
- tngx-20251023_pre.xml (EX-101.PRE) — 11KB
- d80580d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TANGO THERAPEUTICS, INC. Date: October 24, 2025 By: /s/ Daniella Beckman Name: Daniella Beckman Title: Chief Financial Officer